Metabolic & Weight Management Peptides

Peptides 101 / Metabolic & Weight

Incretins · Appetite · Metabolic health

Metabolic & Weight Management Peptides

Start with labelled incretin medicines when appropriate — the strongest evidence tier on this menu — then discuss investigational or historical fragments with honesty.

Modern fitness setting representing metabolic health and body-composition peptide education

Live programs: GLP-1 overview · Weight-loss GLP-1 page

Detail pages coming soon Individual compound profiles will be published after clinical review.

Who this category is for

Adults with overweight/obesity or metabolic goals who want medically supervised appetite and weight management — especially candidates for Health Canada–authorized GLP-1 / GIP therapies — plus patients asking about experimental metabolic peptides they have seen online.

How this differs from GH-axis “fat loss” marketing

Labelled incretin medicines act on gut–brain appetite and metabolic pathways with large Phase 3 programs. That is a different evidence world from GH secretagogues marketed for body recomposition, or from older fragments like AOD-9604. When muscle preservation during weight loss is a concern, we still prioritise protein, resistance training, and sleep — themes shared with responsible peptide education — rather than stacking unauthorized injectables.

Evidence-first: Wegovy®, Zepbound®, Saxenda®, and selected Ozempic® use sit at Grade A for approved indications. Investigational agents remain education-only until Canadian authorization and pharmacy pathways exist.

Compounds on the education menu

Compound Evidence tier Notes
Semaglutide A See live GLP-1 pages — Wegovy / Ozempic contexts differ by indication
Tirzepatide A Zepbound — dual GIP/GLP-1 for weight management when indicated
Retatrutide Investigational Not authorized in Canada; education only — redirect interest to labelled options
AOD-9604 C–D Historical GH-fragment narrative; weaker evidence vs modern incretins
MOTS-c D Mitochondrial peptide interest; no pivotal injectable weight-loss RCTs

Safety snapshot

Labelled GLP-1 / GIP

GI side effects, gallbladder and rare serious risks per product monograph; requires screening, titration, and follow-up by a licensed clinician. Obtain from licensed pharmacy with DIN.

Experimental metabolic peptides

Limited human data; contamination/mislabelling risk if sourced as RUO; do not substitute gray-market vials for authorized incretin therapy.

How Tri-Health approaches metabolic peptides

  1. Assess medical history, medications, and obesity-care goals using clinical guidelines.
  2. Prefer labelled incretin medicines when appropriate — already live at Tri-Health.
  3. Integrate nutrition, activity, and behavioural support; peptides are not magic.
  4. Explain investigational agents (e.g., retatrutide) as pipeline science, not available care.
  5. Monitor response, tolerability, and muscle-preserving lifestyle habits during weight loss.

Cross-links: Peptides 101 hub · GH Secretagogues (if body-composition questions overlap).

← Back to Peptides 101

Book a peptide therapy consult
(905) 605-9355

8611 Weston Rd #4, Woodbridge, ON L4L 9P1

Medical disclaimer (Canada): Educational content from Tri-Health Wellness Centre (Vaughan/Woodbridge, ON). This is not medical advice and does not replace assessment by a licensed clinician. Peptide therapy is individualized after consultation, screening, informed consent, and use of lawfully sourced product through regulated channels. Do not buy or inject “research use only” peptides online. Unauthorized injectable peptides can cause serious harm. Authorized medicines in Canada carry an eight-digit DIN and should be obtained from a licensed pharmacy. Competitive athletes: check WADA/CCES status before any GH-axis or non-approved substance.